Синдром опсоклонуса–миоклонуса

Обложка

Цитировать

Полный текст

Об авторах

Н. А. Шнайдер

ГБОУ ВПО «Красноярский ГМУ им. проф. В.Ф. Войно-Ясенецкого» МЗ РФ

ФГБУЗ КБ № 51 ФМБА России, Железногорск

Автор, ответственный за переписку.
Email: NASchnaider@yandex.ru
Россия

Е. А. Кантимирова

ГБОУ ВПО «Красноярский ГМУ им. проф. В.Ф. Войно-Ясенецкого» МЗ РФ

Email: fake@neicon.ru
Россия

В. А. Ежикова

ГБОУ ВПО «Красноярский ГМУ им. проф. В.Ф. Войно-Ясенецкого» МЗ РФ

КБУЗ «Красноярский краевой онкологический центр им. А.И. Крыжановского»

Email: fake@neicon.ru
Россия

Список литературы

  1. Петрухин А.С., Бембеева Р.Ц., Самойлова М.В. Опсоклонус–миоклонус синдром у детей. Журн невропатол и психиатр 2006;106(2):63–6.
  2. Garg R.K., Kar A.M., Dixit V. Opsoclonus-myoclonus syndrome in an adult: A case report and response to
  3. clonazepam. Indian J Ophthalmol 1996; 44:101–2.
  4. Klaas J.P., Ahlskog J.E., Pittock S.J. et al. Adult-Onset Opsoclonus-Myoclonus Syndrome. Arch Neurol 2012;1–10.
  5. Stejanowicz J., Izycka-Swieszewska E., Drozynska E. Neuroblastoma and opsoclonus – myoclonus – ataxia syndrome – clinical and pathological characteristics. Folia Neuropathol 2008;46(3):176–85.
  6. Tate E., Allison Т., Pranzatelli M. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus myoclonus syndrome. J Pediatr Oncol Nurs 2005;22(1):8–19.
  7. Евтушенко С.К. Паранеопластические неврологические синдромы (клиника, диагностика и возможности лечения). Междунар неврол журн 2011;8(46):9–21.
  8. Gatti G., Simsek S., Kurne A. et al. Paraneoplastic neurological disorders in breast cancer. Breast 2003;12(3):203–7.
  9. Шнайдер Н.А., Дыхно Ю.А., Ежиков а В.В. Клиническая гетерогенность паранеопластического неврологического сндрома. Сиб онколог журн 2011;3(45):82–90.
  10. Rojas-Marcos I., Rousseau A., Keime-Guibert F. et al. Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine 2003;82(3):216–23.
  11. Sa G., Correia C., Pires M. et al. Multiple paraneoplastic syndromes occurring in the same patient: clinical, imaging and neuropathological documentation. Acta Med Port 2006 ;19(6) : 489–93.
  12. Пономарев В.В. Аутоиммунные заболевания в неврологии. Минск: Беларус. навука, 2010. 259 с.
  13. Wong A. An update on opsoclonus. Curr Opin Neurol 2007;20(1): 25–31.
  14. Hadjivassiliou M., Boscolo S., Tongiorgi E. et al. Cerebellar ataxia as a possible organ-specific autoimmune disease. Mov Disord 2008;23:1370–7.
  15. Pranzatelli M.R. The immunopharmacology of the opsoclonusmyoclonus syndrome. Clin Neuropharmacology 1996;19(1):1–47.
  16. Bataller L., Rosenfeld M.R., Graus F. et al. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol 2003;53:347–53.
  17. Murinson B.B, Guarnaccia J.B. Stiffperson syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology 2008;71:1955–8.
  18. Blaes F., Fuhlhuber V., Korfei M. et al. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol 2005;58:313–7.
  19. Graus F., Saiz A., Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol 2009;257:509–17.
  20. Vincent A., Bien C.G., Irani S.R. et al. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011;10:759–72.
  21. Vincent A., Lang B., Kleopa K.A. Autoimmune channelopathies and related neurological disorders. Neuron 2006;52:123–38.
  22. Blaes F., Pike M.G., Lang B. Autoantibodies in childhood opsoclonusmyoclonus syndrome. J Neuroimmunol 2008;201:221–6.
  23. Korfei M., Fuhlhuber V., Schmidt-Woll T. et al. Functional characterisation of autoantibodies from patients with pediatric opsoclonus–myoclonus-syndrome. J Neuroimmunol 2005;170:150–7.
  24. Nemni R., Braghi S., Natali-Sora M.G. et al. Autoantibodies to glutamic acid decarboxylase in palatal myoclonus and epilepsy. Ann Neurol 1994; 36:665–7.
  25. Kirsten A., Beck S., Fithflniber V. New autoantibodies in pediatric opsoclonus myoclonus syndrome. Ann N Y Acad Sci 2007;1110:256–60.
  26. Sabater L., Xifro X., Saiz A. et al. Analysis of antibodies to neuronal surface antigens in adult opsoclonus-myoclonus. J Neuroimmunol 2008;196:188–91.
  27. Blumenthal D.T., Salzman K.l., Digre K.B. et al. Early pathologic findings and long-term improvement in anti-Ma2- associated encephalitis. Neurology 2006;67:146–9.
  28. Pranzatelli M.R., Travelstead A.L., Tate E.D. et al. B- and T-cell markers in opsoclonus-myoclonus syndrome. Neurology 2004;62:1526–32.
  29. Pranzatelli M.R., Tate E.D., Travelstead A.L. et al. Immunologic and clinical responses to Rituximab in a child with opsoclonus-myoclonus syndrome. Pediatrics 2005;115(1):115–9.
  30. Sheela S.R., Mani P.J. Opsoclonusmyoclonus syndrome: response to plasmapheresis. Indian Pediat 2004;41:17.
  31. Bataller L., Graus F., Saiz A. et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001;124:437–43.
  32. Pranzalelli M., Tate E., Travelstead A. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2006;28(9):585–93.
  33. Rostasy K., Wilken В., Baumann M. High dose pulsatile dexam-ethasone therapy in children with opsoclonus myoclonus syndrome. Neuropediatrics 2006;37(5):291–5.
  34. Dalmau J., Rosenfeld M.R. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008;7:327–40.
  35. Giometto B., Grisold W., Vitaliani R. et al. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol 2010;67:330–5.
  36. Graus F., Delattre J.Y., Antoine J.C. et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75:1135–40.
  37. Zuliani L., Graus F., Giometto B. et al. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry 2012;83(6):638–45.
  38. Borg M. Symptomatic myoclonus. Neurophysiol Clin 2006;36(5–6):309–18.
  39. Groiss S.J., Siebler M., Schnitzler A. Full recovery of adult onset opsoclonus– myoclonus syndrome after early immunotherapy: A case report. Movement Disorders 2011;26(10):1805–7.
  40. Ertle F., Behnisch W., Al Mulla N.A. et al. Treatment of neuroblastoma-related opsoclonus–myoclonus–ataxia syndrome with high-dose dexamethasone pulses. Neuroophthalmol 2012;36(4):149–52.
  41. Chang B.H., Koch T., Hopkins K. et al. Neuroblastoma found in a 4-year-old after rituximab therapy for opsoclonus–myoclonus. Pediatr Blood Cancer 2008;50(3):683–7.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Шнайдер Н.А., Кантимирова Е.А., Ежикова В.А., 2013

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 85909 от  25.08.2023.